Wound Infection Prevention & Sepsis Countermeasure Development

The contract involves the development of a drug/device combination product aimed at preventing or treating wound infections and sepsis specifically in battlefield or austere environments. The project is targeted to advance this product to Phase I clinical trials under the FDA 505(b)(2) regulatory pathway, which facilitates the approval process by leveraging existing data. This effort is intended to address critical medical needs encountered by military personnel in challenging settings, ensuring rapid and effective countermeasures against potentially life-threatening infections. Issued by the Army Medical Resources Acquisition Activity under the Department of Defense, the contract is a subcontract with a focus on the pharmaceutical manufacturing sector (NAICS code 325412). The work will be performed in Frederick, capturing the strategic importance of this location for medical research and development. The solicitation was posted on June 16, 2026, with a response deadline of July 17, 2026, highlighting a clear and concise timeline for interested parties. This project underscores a high-priority initiative to enhance battlefield medical capabilities through innovative therapeutic solutions.